Prostate cancer screening: current status and future perspectives.
With the publication of the long-term results of two randomized screening trials and updates to screening guidelines from many organizations, the past 2 years have been eventful in the field of prostate cancer screening. Both the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial--which failed to identify a benefit of screening in a community setting--and the European Randomized Study of Screening for Prostate Cancer--which showed a modest benefit to screening in a clinical trial setting--have sought to address the role of screening in reducing mortality from prostate cancer. Epidemiologic evidence supports the role of PSA screening in the stage and grade migration of prostate cancer, but to date the evidence for its role in changing mortality patterns is more equivocal. As a result, little support exists at present among urologic and cancer prevention organizations for population-based PSA screening. Particularly in the USA, where PSA screening has been relatively widespread, reductions in prostate-cancer-specific mortality are likely to be in part related to improvements in treatment, rather than solely to PSA screening. The substantial risk of overdiagnosis and overtreatment of latent prostate cancer means that methods to increase the specificity of prostate cancer screening, and particularly its ability to identify high-risk disease, are essential. Strategies such as the use of 5alpha-reductase inhibitors in high-risk patients, and the continued development of urinary and genetic markers hold promise in this regard.
Strope
Seth A
SA
Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, St Louis, MO 63110, USA.
Andriole
Gerald L
GL
D005544:Forecasting; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic
J Clin Oncol. 2009 Sep 10;27(26):4300-5
19636023
Cancer. 2009 Sep 1;115(17):3879-86
19517474
Cancer Causes Control. 2008 Mar;19(2):175-81
18027095
CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119
20228384
BMC Med. 2008 Feb 15;6:6
18279502
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
19276453
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54
18695132
Am J Prev Med. 2008 Feb;34(2):164-70
18201648
J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33
16912265
J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3
19713548
BJU Int. 2008 Dec;102(11):1524-30
19035857
J Natl Cancer Inst. 1998 Aug 19;90(16):1230-1
9719085
Nat Rev Urol. 2010 Feb;7(2):101-9
20065953
N Engl J Med. 2009 Mar 26;360(13):1310-9
19297565
Int J Cancer. 2010 May 15;126(10):2387-93
19739124
J Natl Cancer Inst. 2010 Mar 3;102(5):288-9
20142583
Urology. 1998 Sep;52(3):444-8; discussion 448-9
9730458
Urology. 2006 Feb;67(2):316-20
16442597
Cancer Causes Control. 2007 Nov;18(9):931-7
17641982
Lancet Oncol. 2008 May;9(5):445-52
18424233
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
JAMA. 2005 May 4;293(17):2095-101
15870412
Arch Intern Med. 2006 Jan 9;166(1):7-8
16401804
J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9
19720969
J Natl Cancer Inst. 2010 Mar 3;102(5):352-5
20142584
Am J Epidemiol. 2004 Dec 1;160(11):1059-69
15561985
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
N Engl J Med. 2002 Sep 12;347(11):781-9
12226148
N Engl J Med. 2008 Feb 28;358(9):910-9
18199855
Arch Intern Med. 2006 Jan 9;166(1):38-43
16401808
J Natl Cancer Inst. 2003 Jun 18;95(12):868-78
12813170
J Clin Oncol. 2007 Feb 1;25(4):431-6
17264339
J Urol. 2005 Mar;173(3):746-50; discussion 750-1
15711261
Eur Urol. 2009 Aug;56(2):270-1
19481336
JAMA. 2005 Jul 6;294(1):66-70
15998892
Med Decis Making. 2008 May-Jun;28(3):323-31
18319508
BJU Int. 2009 Dec;104(11):1592-8
19549125
N Engl J Med. 2010 Apr 1;362(13):1192-202
20357281
Urology. 2001 Sep;58(3):417-24
11549491
Lancet. 2009 Jan 24;373(9660):301-8
19091394
Lancet Oncol. 2008 May;9(5):407-9
18452850
J Urol. 2003 Oct;170(4 Pt 1):1189-93
14501722
J Urol. 2005 Aug;174(2):495-9; discussion 499
16006879
N Engl J Med. 2008 Feb 28;358(9):961-3
18199856
Lancet. 2000 May 20;355(9217):1788-9
10832832
BMJ. 2002 Oct 5;325(7367):740
12364300
J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53
16145045
Urology. 2001 Sep;58(3):411-6
11549490
Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S
11189684
J Urol. 2011 Jan;185(1):126-31
21074214
Int J Urol. 2008 Sep;15(9):763-8
18786203
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
BJU Int. 2008 Apr;101(7):809-16
18321314
Ann Intern Med. 2008 Aug 5;149(3):192-9
18678846
J Natl Cancer Inst. 2007 Sep 5;99(17):1296-303
17728218
J Natl Cancer Inst. 2007 Dec 19;99(24):1881-7
18073376